Subscribe
Sign in
Home
Notes
Archive
Leaderboard
About
Latest
Top
Discussions
What If We Are Misallocating the Most Powerful Technology of Our Generation?
Healthcare AI investment is a declaration of priorities.
Mar 29
•
Paul J. Swider
1
Microsoft's healthcare AI platform play takes center stage at HIMSS26
On-site analysis from Day 2 of HIMSS26. Analyst coverage under the Cloud Wars press credential.
Mar 20
•
Paul J. Swider
1
1
Microsoft Is 6 Months Away from an AI Powerhouse. Here's Why That Matters for Healthcare
Copilot Tasks, Cowork, and Dragon Copilot are converging into something the enterprise hasn't seen yet. Hospital leaders should be paying attention
Mar 15
•
Paul J. Swider
1
Google Cloud's Agentic Moment in Healthcare
The question in 2026 is not what AI can do. It is what AI can be trusted to do
Mar 13
•
Paul J. Swider
1
Two years ago, at HIMSS, almost no one in healthcare was talking about generative AI
Today at HIMSS 2026, it’s everywhere.
Mar 11
•
Paul J. Swider
Who does the agent work for?
The platform, the health system, or the patient?
Mar 8
•
Paul J. Swider
1
AWS Just Told Every Hospital CIO That Microsoft Was Right About Agents
Why Amazon's OpenAI Deal Is the Biggest Admission of Infrastructure Defeat in the AI Wars, And What It Means for Healthcare
Mar 1
•
Paul J. Swider
1
February 2026
When Microsoft Changes the Model, Who Bears the Risk?
What Microsoft's push toward AI self-sufficiency means for healthcare leaders, and why the time to plan is now.
Feb 20
•
Paul J. Swider
Anthropic's Cowork and OpenClaw Are Coming for the Same Throne
And It Changes Everything About Enterprise AI
Feb 20
•
Paul J. Swider
Microsoft's 2026 Frontier Model: What Healthcare Leaders Need to Know
The tech giant's move to develop independent foundation models signals a strategic pivot that could reshape AI deployment in clinical and operational…
Feb 16
•
Paul J. Swider
2
OpenClaw, Peter Steinberger Just Joined OpenAI
OpenClaw Is Now an Independent Open-Source Foundation. This Is a Big Deal.
Feb 15
•
Paul J. Swider
1
China Just Approved a Homegrown GLP-1 Drug. Here's Why Healthcare Leaders Should Pay Attention.
The incretin market is about to get a lot more competitive, and the implications go well beyond endocrinology.
Feb 11
•
Paul J. Swider
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
